Quadcap Wealth Management LLC Has $1.25 Million Stock Position in Stryker Co. (NYSE:SYK)

Quadcap Wealth Management LLC reduced its stake in Stryker Co. (NYSE:SYK) by 0.8% during the fourth quarter, Holdings Channel.com reports. The fund owned 3,458 shares of the medical technology company’s stock after selling 28 shares during the period. Quadcap Wealth Management LLC’s holdings in Stryker were worth $1,245,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Kohmann Bosshard Financial Services LLC acquired a new position in Stryker in the fourth quarter valued at approximately $25,000. Rakuten Securities Inc. lifted its stake in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company’s stock valued at $28,000 after buying an additional 68 shares during the period. Centricity Wealth Management LLC acquired a new position in Stryker in the fourth quarter valued at approximately $30,000. BankPlus Trust Department acquired a new position in Stryker in the fourth quarter valued at approximately $33,000. Finally, VSM Wealth Advisory LLC acquired a new position in Stryker in the fourth quarter valued at approximately $36,000. 77.09% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms have recently commented on SYK. Wells Fargo & Company boosted their price objective on Stryker from $427.00 to $435.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Argus set a $450.00 price target on Stryker in a report on Monday, February 3rd. Barclays upped their price target on Stryker from $418.00 to $443.00 and gave the stock an “overweight” rating in a report on Monday, February 10th. The Goldman Sachs Group set a $422.00 price target on Stryker in a report on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $442.00 price target on shares of Stryker in a report on Friday, March 21st. Five investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $427.05.

Stryker Stock Down 0.3%

Shares of NYSE SYK opened at $386.42 on Thursday. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32. The business’s fifty day moving average price is $365.58 and its 200-day moving average price is $374.90. The stock has a market capitalization of $147.49 billion, a PE ratio of 49.80, a P/E/G ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK) last issued its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.73 by $0.11. The business had revenue of $5.87 billion for the quarter, compared to analysts’ expectations of $5.68 billion. Stryker had a return on equity of 23.58% and a net margin of 13.25%. The firm’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.50 EPS. On average, equities research analysts anticipate that Stryker Co. will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 31st. Investors of record on Monday, June 30th will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, June 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.87%. Stryker’s dividend payout ratio (DPR) is 45.41%.

Insider Buying and Selling

In other Stryker news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at $5,705,827.65. This represents a 14.16% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ronda E. Stryker sold 200,000 shares of the company’s stock in a transaction dated Tuesday, May 6th. The stock was sold at an average price of $376.96, for a total value of $75,392,000.00. Following the completion of the transaction, the director now owns 3,417,326 shares in the company, valued at $1,288,195,208.96. This represents a 5.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.